The Imminent Digital Revolution in Cardio-Oncology Research – How Natural Language Processing and Large Language Models Will Change Our Methods in the Next Five Years

In the rapidly evolving field of cardio-oncology, the dynamic digital evolution promises to reshape research methodologies and unlock new insights. In our upcoming broadcast, titled 'The Imminent Digital Revolution in Cardio-Oncology Research – How Natural Language Processing and Large Language Models Will Change Our Methods in the Next Five Years' Julius C Heemelaar (Leiden University Medical Center, Leiden, NL) with Prof Dan Lenihan (Saint Francis Healthcare System, US) and Prof Joe Carver (University of Pennsylvania, US) will discuss the complexities of this transformative landscape.

Join us as our faculty navigates through the revolutionary potential of Natural Language Processing and Large Language Models in cardio-oncology research. From exploring cutting-edge techniques to discussing the implications for clinical practice, this webinar promises to be an enlightening journey into the future of cardio-oncology research.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.